An examination of payer coverage for multiple sclerosis drugs shows variation in how these drugs are covered and in the evidence that payers review to make these decisions.
Jordan E. Anderson, BA
Advertisement
Articles by Jordan E. Anderson, BA
Advertisement
Latest Updated Articles
- Variation in the Coverage of Disease-Modifying Multiple Sclerosis Drugs Among US Payers
Published: September 21st 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
3
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
4
Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings
5
